You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
43 search results for: mechanism of disease
videoanimation
Pathways to Disease: Inflammation in Chronic Obstructive Pulmonary Disease Video
Pulmonology
Learn about the significant burden that patients with COPD experience and the role of inflammatory mechanisms in this chronic, often progressive disease.
ERS 2023 | The Impact of Type 2 Inflammation on COPD: Examining Its Role in Disease Pathophysiology
Pulmonology
Prof. Klaus Rabe and Dr. Stephanie Christenson explore COPD's clinical presentation through disease pathology, emphasizing its diverse inflammatory pathways.
PN and AD: Distinct Diseases with Underlying Type 2 Inflammation
Dermatology
Prurigo nodularis (PN) and atopic dermatitis (AD): Distinct diseases with underlying type 2 inflammation – highlights from the ADVENT symposium at AAD 2023.
Dr. Ramien explores the concept ofdisease modification in AD focusing on disease control, and the prevention or slowing of development of atopic comorbidities.
Clinical Aspects and Immunology of COPD and Asthma
Pulmonology
The slide deck provides insights into how Chronic Obstructive Pulmonary Disease (COPD) and asthma are distinct disorders, yet they may share some treatable traits and clinical features
Presentation of atopic dermatitis and prurigo nodularis, and the impact of PN as an intensely pruritic disease – Clip from the ADVENT symposium at AAD 2023.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.